ClinicalTrials.gg

Hyperuricemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 240 studies for Hyperuricemia across more than 10 countries. 44 are recruiting or about to start. 111 of them are mainly about Hyperuricemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
132
Status unknown
38
Recruiting
29
Active, not recruiting
14
Not yet recruiting
13
Terminated
9

Phase

Phase 2
67
Phase 1
42
Phase 4
28
Phase 3
23
Early Phase 1
4

Where

United States
75
China
57
Japan
17
Taiwan
14
France
7
Australia
6

Who develops what

Add Hyperuricemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 19 programs from 9 companies, 5 with this as their studies’ main aim; 2 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Swedish Orphan Biovitrum, Jiangsu HengRui Medicine and Novo Nordisk here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
FebuxostatRecent, repeated
Evidence
  • NCT07498647 · BioRay Pharmaceutical Co., Ltd. · Phase 2 · live · comparator · “Febuxostat” · registered Mar 2026
  • NCT07362355 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Febuxostat” · registered Jan 2026
  • NCT06603142 · Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd · Phase 3 · live · comparator · “Febuxostat 20MG Tablets” · registered Sep 2024
  • NCT06501534 · Innovent Biologics, Inc. · Phase 2 · comparator · “Febuxostat” · registered Jul 2024
  • NCT05513976 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · background · “febuxostat tablet” · registered Aug 2022
Takeda51% of its industry studiesUS: off-patent, 12 generics marketedEU: off-patent, 2 generics authorized45 studies
AllopurinolRecent, repeated
Evidence
  • NCT07089888 · Crystalys Therapeutics · Phase 3 · live · comparator · “Allopurinol” · registered Jul 2025
  • NCT07089875 · Crystalys Therapeutics · Phase 3 · live · comparator · “Allopurinol” · registered Jul 2025
  • NCT05586971 · LG Chem · Phase 3 · comparator · “Allopurinol” · registered Oct 2022
  • NCT02600780 · getz pharma · Phase 4 · comparator · “Allopurinol” · registered Nov 2015
  • NCT02500641 · Menarini Group · Phase 4 · comparator · “Allopurinol 100 up to 600mg/day” · registered Jul 2015
AstraZeneca62% of its industry studiesUS: off-patent, 12 generics marketed23 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Combined metabolic activators☆ Track1 live phase-3 study: NCT07889284ScandiBio Therapeutics AB
dotinurad☆ Track2 live phase-3 studies: NCT07089888, NCT07089875Crystalys Therapeutics

The 2 in phase 3 with the nearest primary completion, of 19 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.AR882, XOI Low Dose · Swedish Orphan Biovitrum · Phase 2 named, not the main aimNCT07116746 Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients — primary endpoint: Serum urate (uric acid) (sUA) level < 6 mg/dL at month 6 · 15 enrolled
  • Feb 2027 est.Combined metabolic activators · ScandiBio Therapeutics AB · Phase 3 main aimNCT07889284 Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout — primary endpoint: To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo. · 336 enrolled
  • Jul 2027 est.ruzinurad · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimvs FebuxostatNCT07362355 The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia — primary endpoint: The proportion of subjects with serum uric acid levels of ≤360 μmol/L at week 12 · 340 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hyperuricemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

16studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger. 1 (3%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (21%) take healthy volunteers.

Recruiting studies that take each age, of 29
AgeWomenMen
101 (3%)1 (3%)
1825 (86%)25 (86%)
3026 (90%)26 (90%)
4028 (97%)28 (97%)
5028 (97%)28 (97%)
6528 (97%)28 (97%)
7521 (72%)21 (72%)
859 (31%)9 (31%)

Across all 240 studies, recruiting or not: 62% stop at 75 or younger and 36% at 65; 5% take children; 1% are for women only and 8% for men only; 33% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperuricemia studies take

Of 31 phase 1 interventional studies under Hyperuricemia, half reached primary completion within 6 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 16 mo1–10 · 31 studies4 mo1–9 · 29 studies—
Phase 214 mo10–26 · 24 studies——
Interventional, no phase14 mo6–34 · 26 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 240. Browse all 240 → or search them.